The effect of Noscapine on clinical and pulmonary manifestations of COVID-19 patients

The effect of NOSCOVID on pulmonary & other clinical manifestations of COVID-19 patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160625028622N1

Enrollment

125

Registered

2020-03-22

Start date

2020-03-19

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Cronavirus Disease (COVID-19). ?????? ?????? ?????

Interventions

Intervention 1: Intervention group: Treatment group which received Noscapine mg, tds. Intervention 2: Control group: Group receiving Placebo with no API.

Eligibility

Sex/Gender

All

Age

2 Years to No maximum

Inclusion criteria

Inclusion criteria: Positive PCR test for Coronavirus (SARS-COV2) CT Scan finding

Exclusion criteria

Exclusion criteria: Patient who use warfarin Patient who ACEI (captopril. enalapril,... )

Design outcomes

Primary

Measure	Time frame
Cough. Timepoint: Daily. Method of measurement: Clinical finding.;O2 Saturation. Timepoint: daily. Method of measurement: Pulse Oximeter.;Radiographic features Findings. Timepoint: Before/After. Method of measurement: Radiography- CT SCAN.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ehsan Aali

Qazvin University of Medical Sciences

en.aali@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026